DIFLUCAN

Compare DIFLUCAN  to:
Compare
Compare

Generic Name for DIFLUCAN

Fluconazole 50mg, 100mg, 200mg; tabs.

Legal Classification:

Rx

Pharmacological Class for DIFLUCAN

Azole.

Manufacturer of DIFLUCAN

Pfizer Labs

Indications for DIFLUCAN

Oropharyngeal, esophageal, systemic candidiasis. Bone marrow transplant prophylaxis. Cryptococcal meningitis. Candida urinary tract infection (UTI), peritonitis.

Adult dose for DIFLUCAN

Individualize. CrCl<50mL/min: reduce dose, see literature. All doses are once daily. Oropharyngeal candidiasis: 200mg on day 1, then 100mg/day for at least 2 wks. Esophageal candidiasis: 200mg on day 1, then 100mg/day for at least 3 wks; treat for at least 2 wks after symptoms resolve; max 400mg/day. Systemic candidiasis: doses of up to 400mg/day have been used. Prophylaxis of candidiasis in bone marrow transplantation: 400mg/day. Cryptococcal meningitis: 400mg on day 1, then 200–400mg/day for 10–12 wks after spinal fluid negative; to suppress relapse in AIDS: 200mg/day. UTI, peritonitis: 50–200mg/day have been used.

Children's dosing for DIFLUCAN

Individualize. CrCl<50mL/min: reduce dose, see literature. All doses are once daily. Neonates: see literature. Over 2 wks of age: Oropharyngeal candidiasis: 6mg/kg on day 1, then 3mg/kg/day for at least 2 wks. Esophageal candidiasis: 6mg/kg on day 1, then 3mg/kg/day for at least 3 wks; treat for at least 2 wks after symptoms resolve; max 12mg/kg/day. Systemic candidiasis: 6–12mg/kg/day have been used. Cryptococcal meningitis: 12mg/kg on day 1, then 6mg/kg/day for 10–12 wks after negative CSF cultures; max 12mg/kg/day; to suppress relapse in AIDS: 6mg/kg/day. Max for all: 600mg/day.

Also:

Contraindications for DIFLUCAN

Concomitant cisapride.

Warnings/Precautions for DIFLUCAN

Proarrhythmic conditions. Monitor liver function. Discontinue if liver disease or progressively worsening rash develops. Elderly. Pregnancy (Cat.C). Nursing mothers: not recommended.

Interactions for DIFLUCAN

See Contraindications. Potentiates warfarin, theophylline, oral hypoglycemics, midazolam. May increase serum levels of phenytoin, cyclosporine, zidovudine, sulfonylureas. Thiazides increase fluconazole levels. Monitor levels and/or effects of cyclosporine, phenytoin, sulfonylureas, rifabutin, tacrolimus, theophylline, warfarin. Cimetidine (oral), rifampin may decrease fluconazole levels. Oral contraceptives: see literature. Avoid other hepatotoxic drugs. Caution with other drugs metabolized by CYP450.

Adverse Reactions for DIFLUCAN

Nausea, headache, rash, vomiting, abdominal pain, diarrhea; hepatotoxicity, exfoliative dermatitis (rare).

How is DIFLUCAN supplied?

Tabs—30
Susp (35mL)—1
IV (200mg, 400mg)—6

Related Disease:

Infections, fungal~systemic antifungals

Related Resources

Oravig available for oropharyngeal candidiasis

August 25, 2010

Strativa has made available Oravig (miconazole buccal tablets) for the treatment of oropharyngeal candidiasis (OPC) in patients ≥16 years of age.

FDA launches "Bad Ad Program" to detect misleading drug ads

May 11, 2010

The FDA's Division of Drug Marketing, Advertising, and Communications (DDMAC) has launched the Bad Ad Program, designed to educate healthcare providers about their role in ensuring that prescription drug advertising and promotion is truthful, and not misleading.

Oravig buccal tablets approved for oropharyngeal candidiasis

April 19, 2010

The FDA has approved Oravig (miconazole buccal tablets, from Strativa) for the treatment of oropharyngeal candidiasis (OPC) in patients ≥16 years of age.

Exel/Exelint infusion set needles recalled

January 26, 2010

FDA notified healthcare professionals of a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets, and Exel/Exelint "Securetouch+" Safety Huber Infusion Sets due to 'coring,' the cutting or dislodging of silicone cores or slivers from the ports into which they are inserted).

FDA accepts NDA for Miconazole Lauriad, a treatment for oropharyngeal candidiasis (OPC)

August 19, 2009

Strativa (a division of Par Pharmaceuticals) announced that the FDA has accepted for filing the New Drug Application (NDA) submitted for miconazole Lauriad mucoadhesive buccal tablets (MBT) for the treatment of oropharyngeal candidiasis (OPC).

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions